Increasing osteoblastic lesions as a manifestation of a major response to gefitinib

Journal of Thoracic Oncology

Volumn 1, Issue 8, 2006, Pages 859-860

  Garfield, David ^a,b  

^a UNIVERSITY OF COLORADO   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GEFITINIB; ZOLEDRONIC ACID; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE;

ADULT; ARTICLE; BONE LESION; BONE SCINTISCANNING; BRAIN METASTASIS; CANCER INFILTRATION; CASE REPORT; CLINICAL FEATURE; COMPUTED TOMOGRAPHY SCANNER; DIAGNOSTIC APPROACH ROUTE; DIAGNOSTIC IMAGING; DIAGNOSTIC TEST; DRUG ERUPTION; FEMALE; HUMAN; LOW BACK PAIN; LUNG NON SMALL CELL CANCER; MEDICAL EXAMINATION; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOBLAST; PRIORITY JOURNAL; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; BONE TUMOR; BRAIN TUMOR; DRUG ANTAGONISM; LUNG TUMOR; METASTASIS; MIDDLE AGED; PATHOLOGY;

ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; BRAIN NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MIDDLE AGED; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 34248399280     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/01243894-200610000-00017     Document Type: Article

References (5)

1. Gurpide A, Perez-Gracia JL, Lopez-Picazo JM, et al. Activity of gefitinib in central nervous system metastases in patients with non-small-cell lung cancer: two case reports and a review of the literature. Clin Lung Cancer. 2006;7:138-140.
2. Sullivan FJ. Palliative radiotherapy. In Pass, HI, Mitchell JB, Johnson DH, et al. (eds.), Lung Cancer, Principles and Practice. Philadelphia: Lippincott Williams & Wilkins, 2000, pp. 1006-1023.
3. Normanno N, De Luca A, Aldinucci D, et al. Gefitinib inhibits the ability of human bone marrow stromal cells to induce osteoclast differentiation: implications for the pathogenesis and treatment of bone metastases. Endocr Relat Cancer. 2006;12:471-482.
4. Lai CSL, Boshoff C, Falzon M, et al. Complete response to erlotinib treatment in brain metastases from recurrent NSCLC (Letter). Thorax 2006;61:91.
5. Riely GJ, Pao W, Miller VA. Selection of patients for epidermal growth factor receptor tyrosine kinase inhibitors. In Lung Cancer, Principles and Practice. Philadelphia, PA: Lippincott Williams & Wilkins; 2006: 5:1-8.